Summary:
SAN DIEGO, April 19, 2022 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTC-BB:AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease (DED), announced today that it has issued the following letter to its shareholders providing commentary on the Company’s recent announcements and upcoming plans.
Read more at globenewswire.com